Board of Directors

Professor Jonathan Blackburn

Chief Scientific Officer

Professor Blackburn is the inventor of the Sengenics KREX™ Protein Array technology. He has more than 35 years background at the highest levels of cutting-edge genomics and proteomics research and development. He invented and developed the KREX™ platform at the University of Cambridge. He leads the R&D team and the strategic direction for developing KREX™ across novel diverse applications for Human disease screening, precision immuno-profiling and therapeutics.

Dato’ Wong Gian Kui

Board Director

Dato’ Wong is a Non-Executive Director who was appointed to the Board of Sengenics in March 2011. He was appointed as Managing Director of Insas in 2000, Chief Executive Officer/Group Managing Director in 2004, and in 2009 was re-designated to Non-Independent & Non-Executive Director of Insas. Prior to joining Insas, Dato’ Wong worked for Harun, Oh & Wong, a member of Howarth International firm of public accountants in Malaysia from 1981 to 1990 and Stoy Hayward London Chartered Accountants from 1990 to 1991. He has been a member of the Malaysian Institute of Accountants since 1988 and of the Malaysian Institute of Certified Public Accountants since 1985.

Dr Arif Anwar

Managing Director and Board Director

Prior to his current role at Sengenics, Dr Anwar held progressively senior positions in genomics, bioinformatics and proteomics companies in the Bay Area in California, the UK and most recently in Singapore. He has a prodigious track record spanning more than twenty years of success in commercialising cutting-edge life science technologies. Out of the five companies he has been involved in, two were acquired, and two went on to successful IPOs. His previous roles included Commercial Director of PhenoCure UK Ltd., a biopharmaceutical company he co-founded in Cambridge, England; Regional Director at DoubleTwist Inc. of Oakland, California and Regional Manager of Clontech of Palo Alto, California. He holds a PhD in Biochemistry which was awarded in 1996 by UCL, London; and a BSc in Genetics in 1993 also from London. Dr Anwar has overall responsibility for the corporate strategy and operations of Sengenics.

Johan Poole-Johnson

Chief Commercial Officer

Johan’s primary role is to devise and implement the commercial strategy for the company which is focused on application of the KREX technology for the identification of autoantibody biomarkers for early diagnostics or stratification of patients undergoing treatment with autoimmune or cancer drugs. He has nearly two decades of industry experience working in high-technology and biotechnology companies, initiating and managing research projects, strategic partnerships and collaborations in the USA, Europe and Japan.


Protein Array

sero-profiling platform

Protein Array

Screening of
cancer-testis antigens

OncoREX p53
Cancer Array

Cancer drug
screening and discovery

Protein Array

Flexible format for
high-throughput screening

Sengenics - Functional Proteomics | Krex Technology | Protein Array Supplier

Sengenics is a functional proteomics company that leverages its patented KREX technology for production of full-length, correctly folded and functional proteins. The key application of KREX is the discovery of autoantibody biomarkers for two core medical use cases:  stratification of patients undergoing treatment with autoimmune or cancer drugs and identification of autoantibody biomarkers that may be used to diagnose cancer, autoimmune or neurodegenerative conditions. Some autoantibodies that are identified as diagnostic biomarkers may be protective and have potential in themselves as therapeutic biomolecules.

Find Us On:

© 2008 – 2021 Sengenics All rights reserved | Sengenics Corporation Pte Ltd. Registered in Singapore no. 201734100D | Sengenics UK Ltd. Registered in England and Wales No 11016361